【摘要】 目的　观察协良行与左旋多巴合用治疗帕金森病的疗效及安全性等。方法　选择特发性帕金森病 2 6例 ,在原有的治疗基础上加用协良行 0 .5～ 1.5 mg/ d,并分别比较其治疗前后 PDRS(简化帕金森病分级量表评分 )、改良Hoehn- Yahr分级评分等变化。结果　加用协良行后患者其日常活动能力评分、运动功能评分、“关”状态时数、Hoehn-Yahr分级评分及 PDRS总评分均较治疗前显著改善 ,P<0 .0 5。结论　协良行作为左旋多巴的联用药物 ,可明显改善帕金森病患者的临床症状及减少左旋多巴用量 ,且安全可靠。更多还原

【Abstract】 Objective To assess the efficacy and safety of pergolide as an adjunct to levodopa in Parkinsons disease.Methods Twenty six patients with Parkinsons disease participated in the study.Patients were given 0.5～1.0mg of pergolide daily for 24 weeks.The ir PRDS(Unified Parkinsons Disease Rating Scale)and Hoehn and Yahr score were measured entry and at the thd of the study.Results There were significant differences betwen entry and the tnd of the study in score of activities of daily living,score of motor,number of "off" hours per day,Hoehr and Yahr score,and PDRS( P <0.05).Conclusion This study demonstrates that pergolide,as an adjunct to levodopa,is a safe and effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.更多还原